KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Current Deferred Revenue (2018 - 2025)

Adaptive Biotechnologies' Current Deferred Revenue history spans 8 years, with the latest figure at $45.2 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 18.85% year-over-year to $45.2 million; the TTM value through Dec 2025 reached $45.2 million, down 18.85%, while the annual FY2025 figure was $45.2 million, 18.85% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $45.2 million at Adaptive Biotechnologies, up from $41.3 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $179.2 million in Q4 2021 and bottomed at $41.3 million in Q3 2025.
  • The 5-year median for Current Deferred Revenue is $62.9 million (2022), against an average of $78.7 million.
  • The largest annual shift saw Current Deferred Revenue surged 144.43% in 2021 before it tumbled 62.64% in 2023.
  • A 5-year view of Current Deferred Revenue shows it stood at $179.2 million in 2021, then plummeted by 31.53% to $122.7 million in 2022, then crashed by 60.37% to $48.6 million in 2023, then rose by 14.52% to $55.7 million in 2024, then decreased by 18.85% to $45.2 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Current Deferred Revenue are $45.2 million (Q4 2025), $41.3 million (Q3 2025), and $55.3 million (Q2 2025).